Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases
With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions.
Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer immunotherapy.
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use), a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial). Nivolumab for subcutaneous use co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The CHMP opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines in the European Union (EU).
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
